Anti-Human ApoE4 (Clone 4E4) – Purified in vivo GOLD^TM Functional Grade

Synthetic peptide made to an internal region of human ApoE4

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only (RUO). Non-Therapeutic.

2-8°C Wet Ice

4E4 activity is specific to ApoE4, recognizing an internal domain present exclusively in the ApoE4 isoform.

ApoE is produced differentially in the central nervous system by astrocytes and microglia as well as peripherally by the liver and macrophages. ApoE does not cross the blood–brain barrier.

Apolipoprotein E (ApoE) is a glycoprotein involved in lipid metabolism encoded by three isoforms, ApoE2, ApoE3, and ApoE4, which differ at residues 112 and 158 (E2: C112, C158; E3: C112, R158; E4: R112, R158)¹. Carriers of the ApoE4 isoform are more likely to develop Alzheimer’s Disease (AD), with cognitive changes also occurring earlier². ApoE4 has been implicated in increased amyloid β deposition, a key marker of AD, and has an effect on lipid metabolism, inflammation, phosphorylation of tau protein, and mitochondrial function. ApoE4 is also a risk factor for cerebral amyloid angiopathy, dementia with Lewy bodies, tauopathy, cerebrovascular disease, multiple sclerosis, vascular dementia, and is related to poor outcome following head injury. In contrast, ApoE4 is protective for age-related macular degeneration. Lower concentrations of ApoE are found in ApoE4 carriers. However, it is unknown how the amount of ApoE4 present intersects with its functional activity to increase risk of disease. Anti-ApoE4 therapies that aim to mitigate the pathological effects of ApoE4 and inhibit amyloid accumulation are under study.

1. Veiga S, Rodríguez-Martín A, Garcia-Ribas G, et al. Sci Rep. 10(1):2138. 2020.
2. Safieh M, Korczyn AD, Michaelson DM. BMC Med. 17(1):64. 2019.
3. Calero O, García-Albert L, Rodríguez-Martín A, et al. Sci Rep. 8(1):5969. 2018.
4. Kotredes KP, Oblak A, Pandey RS, et al. Front Aging Neurosci. 13:735524. 2021.
5. Qi G, Mi Y, Shi X, et al. Cell Rep. 34(1):108572. 2021.
6. Lennol MP, Sánchez-Domínguez I, Cuchillo-Ibañez I, et al. Alzheimers Res Ther. 14(1):161. 2022.
7. Sepulveda J, Luo N, Nelson M, et al. J Neurochem. 163(3):247-259. 2022.
8. Foley KE, Hewes AA, Garceau DT, et al. Front Aging Neurosci. 14:838436. 2022.
9. Zhang M, Gong W, Zhang D, et al. Cell Death Dis. 13(4):406. 2022.